We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 41 to 50
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LOKELMA sodium zirconium cyclosilicate hydrate 10 g powder for oral suspension sachet.
-
Australian public assessment report (AusPar)Lokelma (sodium zirconium cyclosilicate hydrate) was approved for the treatment of hyperkalaemia (high potassium levels in blood) in adult patients.
-
Australian public assessment report (AusPar)Enhertu (trastuzumab deruxtecan) was approved to treat adult patients with unresectable or metastatic HER2-low breast cancer.
-
Australian public assessment report (AusPar)Sidapvia (dapagliflozin+sitagliptin), a new drug combination, has been approved to treat type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control.
-
-
Australian public assessment report (AusPar)Lynparza (olaparib) has been approved for the treatment of BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer.
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.5 mg/ml nebuliser suspension.